Goldman Sachs analysts added Alnylam (ALNY) to the firm’s US Conviction List as part of its monthly update. The company is at an inflection point as its key asset, Amvuttra’s, will likely launch in ATTR-cardiomyopathy, which will drive the next leg of growth, the firm contends. It has a Buy rating on Alnylam with a $371 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
Questions or Comments about the article? Write to editor@tipranks.com